Roche at SABCS 2017, 05-09 Dec San Antonio, TX
Welcome to Roche at SABCS 2017
The San Antonio Breast Cancer Symposium (SABCS) is designed to provide state-of-the-art information on breast cancer and premalignant breast disease to an international audience of academics, physicians and researchers. Educational sessions, award lectures, case discussions and forums aim to offer a comprehensive scientific meeting on breast cancer research.
SABCS 2017 - Dec 5-9, San Antonio, TX
Discover Roche’s information from SABCS 2017 on this page, including the latest clinical trial data on breast cancer.
Latest on Medically from SABCS 2017
SABCS 2017 poster- Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-positive breast cancer
Poster describing the prevelance and severity of diarrhea in the APHINITY study.
SABCS 2017 poster- Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study
Poster describing the safety of neoadjuvant to adjuvant pertuzumab-trastuzumab based regimens in the BERENICE study.
SABCS 2017 poster- Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years’ treatment free follow-up: Final analysis from the phase III, open-label, randomized HannaH study
Poster describing efficacy and safety of trastuzumab IV vs trastuzumab SC up to 5 years post treatment in the HannaH study.
SABCS 2017 poster- IMpassion031: A Phase III Study Comparing Neoadjuvant Atezolizumab vs Placebo in Combination With Nab-Paclitaxel–Based Chemotherapy in Early Triple-Negative Breast Cancer (TNBC)
Poster describing the rationale and study design of IMpassion 031 (atezolizumab in neoadjuvant TNBC).
SABCS 2017 poster-IMpassion131: A Phase III Study Comparing 1L Atezolizumab With Paclitaxel vs Placebo With Paclitaxel in Treatment-Naive Patients With Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Poster describing the rationale and study design of IMpassion 131 (atezolizumab plus paclitaxel vs. paclitaxel in mTNBC).
SABCS 2017 poster- Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo)
Poster describing the impact of treatment with atezolizumab on tumoral molecular characteristics in mTNBC.